查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1712541

全球胃癌治疗市场 - 2025-2033

Global Gastric Cancer Treatment Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年全球胃癌治疗市场规模达58.2亿美元，预计2033年将达到146.6亿美元，2025-2033年预测期内的复合年增长率为10.9%。

胃癌，也称为胃癌，是指始于胃内壁细胞的一种癌症。它是世界上最常见和最致命的癌症之一，在东亚、欧洲和南美洲部分地区尤其常见。胃癌可以在胃的任何部位发展，并可能扩散到其他器官，如食道、胰臟、肝臟和淋巴结。

胃癌主要起源于胃壁上皮细胞，导致腺癌，这是最常见的胃癌类型（约占 90-95％ 的病例）。然而，胃癌也包括其他较为罕见的形式，如淋巴瘤（淋巴组织癌）、胃肠道间质瘤（GIST）和神经内分泌肿瘤。

市场动态：

驾驶员和约束装置

标靶治疗的不断进步显着推动了胃癌治疗市场的成长

胃癌治疗中最显着的进步之一是 HER2 标靶疗法的开发。 HER2（人类表皮生长因子受体 2）是一种在某些胃癌细胞中过度表现的蛋白质，导致细胞生长不受控制。曲妥珠单抗（赫赛汀）是一种针对 HER2 的单株抗体，是 HER2 阳性胃癌的突破性治疗方法。这种治疗方法的成功使得它与化疗联合治疗晚期胃癌被广泛使用。

例如，2024年10月，安斯泰来製药公司宣布，美国食品药品监督管理局（FDA）批准VYLOY（zolbetuximab-clzb）联合含氟嘧啶和铂类化疗，用于一线治疗局部晚期不可切除或转移性人表皮生长因子受体2（HER2）阴性胃腺癌或胃食管连接部（CLGEFDA）检测VYLOY 是美国首个也是唯一一个核准的 CLDN18.2 标靶疗法

标靶治疗的不断进步成为胃癌治疗市场成长的重要动力。朝向更个人化和有效的治疗转变，加上 FDA 对新药的批准、不断增长的市场接受度以及患者存活率的提高，都促进了这一增长。随着该领域研究的不断深入，预计标靶治疗将更加精细化，为胃癌患者带来更大的希望，市场规模也将进一步扩大。

与治疗相关的副作用和安全问题阻碍了市场的成长

儘管胃癌治疗取得了重大进展，但副作用和安全问题仍然是疾病管理的重大挑战。传统疗法和标靶疗法的不良反应常常使患者不愿遵守规定的治疗方案，影响他们的生活质量，并使治疗方案复杂化。这些担忧反过来又阻碍了胃癌治疗市场的广泛应用和成长。

化疗仍然是胃癌治疗的基石，但它会带来一系列严重的副作用。这些可能导致剂量减少、治疗停止和生活品质下降，最终阻碍市场成长。虽然标靶治疗和免疫疗法彻底改变了胃癌治疗，但这些疗法并非没有风险。儘管它们的副作用往往比化疗少，但它们仍然可能导致严重的免疫相关不良事件（irAE）或脱靶效应。

流行病学分析

胃癌的发生率呈上升趋势。根据DataM情报估计，2024年全球患病人数预计将接近102万，其中亚太地区患病人数最多，达1.9028亿。透过筛检进行早期发现、更好的治疗选择以及改善的公共卫生措施促使已开发国家的发病率和死亡率下降。然而，胃癌仍然是一个沉重的医疗负担，特别是在发展中国家和高风险族群。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 癌症类型片段
  • 按治疗类型分类的片段
  • 依给药途径分类的片段
  • 按地区分类的片段

第三章：动态

  • 影响因素
    • 驱动程式
      • 标靶治疗的进展
      • 扩大临床试验和研究投资
    • 限制
      • 副作用和安全问题
      • 治疗费用高昂
    • 机会
      • 治疗方案的进展
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大行销品牌的既定领导者
    • 拥有成熟产品的市场领导者
  • 最新进展与突破
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 管道分析
  • 流行病学分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第五章：胃癌治疗市场（依癌症类型）

  • 非贲门（远端）胃癌
  • 近端胃癌
  • 瀰漫性胃癌
  • 淋巴瘤
  • 胃肠道间质瘤
  • 类癌肿瘤
  • 腺癌
  • 其他的

第六章：胃癌治疗市场（依治疗类型）

  • 化疗
    • 卡培他滨
    • 顺铂
    • 多西他赛
    • 阿霉素
    • 表柔比星
    • 氟尿嘧啶（5-FU）
    • 伊立替康
    • 亚叶酸钙
    • 奥沙利铂
    • 紫杉醇
    • 其他的
  • 放射治疗
  • 标靶治疗
    • 雷莫芦单抗
    • 瑞戈非尼
    • 曲妥珠单抗
    • 佐贝妥昔单抗
    • 其他的
  • 免疫疗法
    • 纳武单抗
    • 帕博利珠单抗
  • 手术
    • 胃切除术
    • 胃空肠吻合术
    • 其他的
  • 其他的

第七章：胃癌​​治疗市场（依给药途径）

  • 注射剂
  • 口服

第八章：胃癌治疗市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • Merck & Co., Inc.
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • Eli Lilly and Company
  • Genentech USA, Inc.
  • Pfizer Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Blueprint Medicines Corporation
  • Daiichi Sankyo, Inc.
  • BeiGene, Ltd.
  • Ipsen Biopharmaceuticals Inc.
  • Taiho Oncology, Inc.
  • Deciphera Pharmaceuticals, LLC.

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: PH9517

The global gastric cancer treatment market size reached US$ 5.82 billion in 2024 and is expected to reach US$ 14.66 billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033.

Gastric cancer, also known as stomach cancer, refers to a type of cancer that begins in the cells lining the stomach. It is one of the most common and deadly forms of cancer worldwide, particularly prevalent in East Asia, Europe, and parts of South America. Gastric cancer can develop in any part of the stomach and may spread to other organs, such as the esophagus, pancreas, liver, and lymph nodes.

Gastric cancer primarily originates from the epithelial cells that line the stomach, leading to adenocarcinoma, which is the most common type of gastric cancer (around 90-95% of cases). However, gastric cancer can also include other, rarer forms such as lymphoma (cancer of lymphatic tissue), gastrointestinal stromal tumors (GISTs), and neuroendocrine tumors.

Market Dynamics: Drivers & Restraints

Rising advancements in targeted therapies are significantly driving the gastric cancer treatment market growth

One of the most notable advancements in gastric cancer treatment has been the development of HER2-targeted therapies. HER2 (human epidermal growth factor receptor 2) is a protein overexpressed in some gastric cancer cells, leading to uncontrolled cell growth. Trastuzumab (Herceptin), a monoclonal antibody targeting HER2, has been a groundbreaking treatment for HER2-positive gastric cancer. The success of this treatment has led to its widespread use in combination with chemotherapy for advanced gastric cancer.

For instance, in October 2024, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) approved VYLOY (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test. VYLOY is the first and only CLDN18.2-targeted therapy approved in the U.S.

The rising advancements in targeted therapies have been a significant driver for the growth of the gastric cancer treatment market. The shift towards more personalized and effective treatments, combined with the FDA approvals of new drugs, the growing market acceptance, and the increased survival rates in patients, all contribute to this growth. As the research in this field continues to progress, it is expected that targeted therapies will become even more refined, offering greater hope for gastric cancer patients and expanding the market further.

Side effects and safety concerns associated with the treatment are hampering the market growth

Despite the significant advancements in gastric cancer treatment, side effects and safety concerns continue to pose major challenges in the management of the disease. The adverse effects associated with both traditional and targeted therapies often deter patients from adhering to prescribed regimens, impact their quality of life, and complicate treatment regimens. These concerns, in turn, hinder the widespread adoption and growth of the gastric cancer treatment market.

Chemotherapy remains a cornerstone of treatment for gastric cancer, but it is associated with a range of severe side effects. These can lead to dose reductions, discontinuation of therapy, and decreased quality of life, which ultimately hampers market growth. While targeted therapies and immunotherapies have revolutionized gastric cancer treatment, these therapies are not without their risks. Although they tend to have fewer side effects than chemotherapy, they can still cause severe immune-related adverse events (irAEs) or off-target effects.

Epidemiology Analysis

The incidence of gastric cancer is rising. As per DataM intelligence estimates, nearly 1.02 million prevalent cases are estimated worldwide in 2024. The region with the highest prevalence is the Asia-Pacific, accounting for 190.28 million cases. Early detection through screening, better treatment options, and improved public health measures have contributed to the decline in incidence and mortality rates in developed countries. However, gastric cancer continues to present a major healthcare burden, particularly in developing nations and among high-risk populations.

Segment Analysis

The global gastric cancer treatment market is segmented based on cancer type, treatment type, route of administration, and region.

Treatment Type:

The chemotherapy segment is expected to dominate the gastric cancer treatment market with the highest market share

Chemotherapy is frequently used as the primary treatment in advanced gastric cancer, often in combination with targeted therapies or immunotherapy. In cases where surgery is not possible, chemotherapy serves as a crucial palliative treatment to control symptoms, slow the disease's progression, and improve survival rates. For instance, FOLFOX (a combination of 5-fluorouracil (5-FU), oxaliplatin, and leucovorin) is a standard chemotherapy regimen used in gastric cancer. This regimen is particularly effective for advanced gastric cancer and has been widely adopted.

Chemotherapy is frequently combined with targeted therapies like trastuzumab, ramucirumab, and nivolumab to enhance efficacy, especially in advanced or metastatic gastric cancer. These combination regimens have become the standard of care in many treatment protocols. The growing trend of combining chemotherapy with newer therapies has expanded its market dominance, as it remains the central component of first-line and second-line treatment regimens in both HER2-positive and HER2-negative gastric cancers.

Geographical Analysis

North America is expected to hold a significant position in the global gastric cancer treatment market with the highest market share

The FDA (U.S. Food and Drug Administration) and Health Canada are at the forefront of regulatory approvals for new cancer therapies, including those for gastric cancer. These agencies have fast-tracked and drug approvals for novel treatments like TEVIMBRA (tislelizumab-jsgr), nivolumab (Opdivo), trastuzumab (Herceptin), and ramucirumab (Cyramza). This further accelerates the market growth in the region with various effective treatments.

For instance, in December 2024, BeiGene, Ltd., a global oncology company that intends to change its name to BeOne Medicines Ltd., announced the U.S. Food and Drug Administration (FDA) approved TEVIMBRA (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (>=1).

North America has been a leader in adopting targeted therapies and immunotherapies, which are increasingly used to treat gastric cancer. The region's healthcare system supports the use of expensive, but highly effective, biologics and immunotherapy drugs that target specific proteins or immune checkpoints involved in cancer progression. For instance, Trastuzumab (Herceptin) is widely used for HER2-positive gastric cancer, and its combination with chemotherapy has led to better survival rates. Nivolumab (Opdivo), an immune checkpoint inhibitor, is also approved for use in gastric cancer and has been shown to significantly improve survival in combination with chemotherapy.

Competitive Landscape

Top companies in the gastric cancer treatment market include Merck & Co., Inc., Eli Lilly and Company, Genentech USA, Inc., Pfizer Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Blueprint Medicines Corporation, Daiichi Sankyo, Inc., BeiGene, Ltd., Ipsen Biopharmaceuticals Inc., Taiho Oncology, Inc., and Deciphera Pharmaceuticals, LLC., and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global gastric cancer treatment market report delivers a detailed analysis with 68 key tables, more than 61 visually impactful figures and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Cancer Type
  • 2.4. Snippet by Treatment Type
  • 2.5. Snippet by Route of Administration
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Advancements in Targeted Therapies
      • 3.1.1.2. Expanding Clinical Trials and Research Investment
    • 3.1.2. Restraints
      • 3.1.2.1. Side Effects and Safety Concerns
      • 3.1.2.2. High Treatment Costs
    • 3.1.3. Opportunity
      • 3.1.3.1. Advancements in Treatment Options
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. Latin America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Pipeline Analysis
  • 4.9. Epidemiology Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Gastric Cancer Treatment Market, By Cancer Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 5.1.2. Market Attractiveness Index, By Cancer Type
  • 5.2. Non-Cardia (Distal) Stomach Cancer*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Proximal Stomach Cancer
  • 5.4. Diffuse Stomach Cancer
  • 5.5. Lymphomas
  • 5.6. Gastrointestinal Stromal Tumors
  • 5.7. Carcinoid Tumors
  • 5.8. Adenocarcinoma
  • 5.9. Others

6. Gastric Cancer Treatment Market, By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Chemotherapy*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Capecitabine
    • 6.2.4. Cisplatin
    • 6.2.5. Docetaxel
    • 6.2.6. Doxorubicin
    • 6.2.7. Epirubicin
    • 6.2.8. Fluorouracil (5-FU)
    • 6.2.9. Irinotecan
    • 6.2.10. Leucovorin
    • 6.2.11. Oxaliplatin
    • 6.2.12. Paclitaxel
    • 6.2.13. Others
  • 6.3. Radiation Therapy
  • 6.4. Targeted Therapy
    • 6.4.1. Ramucirumab
    • 6.4.2. Regorafenib
    • 6.4.3. Trastuzumab
    • 6.4.4. Zolbetuximab
    • 6.4.5. Others
  • 6.5. Immunotherapy
    • 6.5.1. Nivolumab
    • 6.5.2. Pembrolizumab
  • 6.6. Surgery
    • 6.6.1. Gastrectomy
    • 6.6.2. Gastrojejunostomy
    • 6.6.3. Others
  • 6.7. Others

7. Gastric Cancer Treatment Market, By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration
  • 7.2. Injectable*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Oral

8. Gastric Cancer Treatment Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. UK
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. China
      • 8.4.6.2. India
      • 8.4.6.3. Japan
      • 8.4.6.4. South Korea
      • 8.4.6.5. Rest of Asia-Pacific
  • 8.5. South America
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. Brazil
      • 8.5.6.2. Argentina
      • 8.5.6.3. Rest of South America
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Merck & Co., Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue's
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Eli Lilly and Company
  • 10.3. Genentech USA, Inc.
  • 10.4. Pfizer Inc.
  • 10.5. Astellas Pharma Inc.
  • 10.6. Bristol-Myers Squibb Company
  • 10.7. Blueprint Medicines Corporation
  • 10.8. Daiichi Sankyo, Inc.
  • 10.9. BeiGene, Ltd.
  • 10.10. Ipsen Biopharmaceuticals Inc.
  • 10.11. Taiho Oncology, Inc.
  • 10.12. Deciphera Pharmaceuticals, LLC.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us